Seoane, Jose A. http://orcid.org/0000-0002-3856-9177
Kirkland, Jacob G. http://orcid.org/0000-0001-5617-7065
Caswell-Jin, Jennifer L.
Crabtree, Gerald R. http://orcid.org/0000-0001-9685-7911
Curtis, Christina http://orcid.org/0000-0003-0166-3802
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-16-1-0084)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA217851, T32CA09151)
Susan G. Komen (PDF16377256)
Article History
Received: 27 September 2018
Accepted: 12 September 2019
First Online: 7 November 2019
Competing interests
: G.R.C. is the founder and a stockholder of Foghorn Therapeutics. C.C. is a scientific advisor to GRAIL and reports stock options as well as consulting for GRAIL and Genentech. J.A.S., J.G.K. and J.L.C.-J. declare no competing interests.